Literature DB >> 6469513

A comparative study of therapeutic activity, myelotoxicity and DNA damage in the bone marrow of mice after cyclophosphamide and ASTA Z 7557 (INN mafosfamide).

M R Berger, P Bedford, W J Zeller, M Kaufmann.   

Abstract

This study compares the two oxazaphosphorine compounds ASTA Z 7557 (AZ) and cyclophosphamide (CP) in their therapeutic activity as well as in their myelotoxicity and DNA damage being induced after a single intraperitoneal injection. Therapeutic activity was determined towards methylnitrosourea-induced rat mammary carcinomas in vivo and in vitro, resulting in comparable efficacy of both compounds at their optimal doses, respectively, with the sensitivity of individual tumors being reflected by the degree of inhibition of 3H-thymidine uptake of these cells in vitro. Myelotoxicity was measured as inhibition of pluripotent (CFU-S) and macrophage-granulocyte committed (CFU-C) stem cells together with the extent of single strand breaks and DNA-DNA interstrand crosslinks in murine bone marrow. At equimolar base AZ was found to induce a higher level of DNA damage than CP in the bone marrow of mice 16 hours after a single intraperitoneal injection. Both compounds depressed the pluripotent stem cell compartment of the bone marrow to a similar extent, whereas AZ was significantly less toxic to the granulocyte cell lineage.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6469513     DOI: 10.1007/bf00232349

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  16 in total

1.  Erythroid progenitors in mouse bone marrow detected by macroscopic colony formation in culture.

Authors:  N N Iscove; F Sieber
Journal:  Exp Hematol       Date:  1975-01       Impact factor: 3.084

2.  A direct measurement of the radiation sensitivity of normal mouse bone marrow cells.

Authors:  J E TILL; E A McCULLOCH
Journal:  Radiat Res       Date:  1961-02       Impact factor: 2.841

3.  Screening of cytotoxic drugs for residual bone marrow damage.

Authors:  K J Trainor; A A Morley
Journal:  J Natl Cancer Inst       Date:  1976-12       Impact factor: 13.506

4.  Improved microfluorometric DNA determination in biological material using 33258 Hoechst.

Authors:  C F Cesarone; C Bolognesi; L Santi
Journal:  Anal Biochem       Date:  1979-11-15       Impact factor: 3.365

5.  Cyclophosphamide. Drug interactions and bone marrow transplantation.

Authors:  K Kovacs; A D Steinberg
Journal:  Transplantation       Date:  1972-03       Impact factor: 4.939

6.  Pretherapeutic detection of tumour resistance and the results of tumour chemotherapy.

Authors:  M Volm; K Wayss; M Kaufmann; J Mattern
Journal:  Eur J Cancer       Date:  1979-07       Impact factor: 9.162

Review 7.  Cyclophosphamide: use in practice.

Authors:  M E Gershwin; E J Goetzl; A D Steinberg
Journal:  Ann Intern Med       Date:  1974-04       Impact factor: 25.391

8.  Cytotoxicity and DNA cross-linking activity of 4-sulfidocyclophosphamides in mouse leukemia cells in vitro.

Authors:  L C Erickson; L M Ramonas; D S Zaharko; K W Kohn
Journal:  Cancer Res       Date:  1980-11       Impact factor: 12.701

9.  Effect of dose, schedule, and route of administration on the in vivo toxicity and antitumor activity of two activated sulfhydryl derivatives of cyclophosphamide.

Authors:  L M Ramonas; L C Erickson; H Ringsdorf; D S Zaharko
Journal:  Cancer Res       Date:  1980-10       Impact factor: 12.701

10.  Synthesis and preliminary antitumor evaluation of 4-(SR)-sulfido-cyclophosphamides.

Authors:  G Peter; H J Hohorst
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

View more
  2 in total

Review 1.  Bone marrow purging with mafosfamide--a critical survey.

Authors:  H Sindermann; M Peukert; P Hilgard
Journal:  Blut       Date:  1989-11

2.  Antineoplastic activity of ASTA Z 7557 (INN mafosfamide) in transplanted and autochthonous experimental rodent tumors.

Authors:  W J Zeller; M R Berger; R Matys; J Schuhmacher
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.